People with ultra-high-risk multiple myeloma may respond poorly to treatment, relapse quickly after they have had chemotherapy, and have a poor prognosis. However, new treatment options such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibody approaches are showing promise for these patients, says Gareth J. Morgan, MD, PhD, professor in the at NYU Grossman School of 鶹 and director of multiple myeloma research at NYU Langone Health’s Perlmutter Cancer Center.
“The results we see in relapsed/refractory patients with these agents really suggest they’re going to be game changers for ultra-high-risk myeloma,” Dr. Morgan says. “And it’s making me very excited for the change that it’s going to bring about for patients.”
Watch and read more from .